Biocon and Mylan Report the US FDA Acceptance of BLA for Proposed Biosimilar of Avastin (bevacizumab)
Shots:
- The US FDA has accepted the BLA for Mylan’s MYL-1402O- a proposed biosimilar to Avastin (bevacizumab) for review under the 351(k)pathway with its anticipated BsUFA date as Dec 27- 2020
- The BLA is based on P-III study assessing proposed biosimilar bevacizumab vs Avastin along with CT for 18wks. in 671 patients with stage 4 non-sq. NSCLC- after which patients continued to monothx. until 42wks. The P-III study resulted in meeting its 1EPs @18wks.
- The companies anticipate approval of MYL-14020 + fluorouracil-based CT as 1L & 2L treatment for m-CRC and as a 1L treatment in combination with interferon alfa for non-sq. NSCLC- recurrent glioblastoma- m-RCC and persistent- recurrent or metastatic cervical cancer
Click here to read full press release/ article | Ref: Biocon | Image: Pinterest
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com